Jenkins' Retirement From US FDA Was Several Years In The Making
Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.
You may also be interested in...
US FDA's Office Of New Drugs Reorganization Approved, But Not Happening Overnight
OND will grow to eight offices and 27 clinical divisions, which is slightly different than an early proposal.
US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large
Uncertainty about Brexit's impact on the FDA-EMA mutual recognition agreement are among issues worrying regulators as countdown continues to the UK's departure from the EU.
US FDA Office Of New Drugs Likely To Be Headed By Deputy Director Stein
Peter Stein is a familiar face within OND and has been working alongside CDER Director Janet Woodcock on the proposed “modernization” of OND. As a previous recruit from outside FDA, Stein has had time to make the key connections and adjustments to working inside government.